{"DataElement":{"publicId":"3179047","version":"1","preferredName":"Person Malignant Neoplasm Recurrent Disease Disease Progression Therapeutic Procedure Receive Ind-2","preferredDefinition":"the yes/no indicator whether a person has received non-cytoxic therapeutic agents to produce an effect that is intended to alter the course of a pathologic process following the return of signs and symptoms of cancer after a period of improvement.","longName":"3178966v1.0:2404918v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3178966","version":"1","preferredName":"Person Malignant Neoplasm Recurrent Disease Disease Progression Therapeutic Procedure Receive","preferredDefinition":"information related to a person having received non-cytoxic therapeutic agents to produce an effect that is intended to alter the course of a pathologic process following the return of signs and symptoms of cancer after a period of improvement.","longName":"2236731v1.0:3178964v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3178964","version":"1","preferredName":"Malignant Neoplasm Recurrent Disease Disease Progression Therapeutic Procedure Receive","preferredDefinition":"A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004:the return of a sign, symptom, or disease after a remission.:Cancer that continues to grow or spread.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:To take, accept, or got something offered.","longName":"3178964v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Recurrent Disease","conceptCode":"C38155","definition":"The return of a disease after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Disease Progression","conceptCode":"C17747","definition":"A process that manifests as the worsening of a disease over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"986ADE98-70B2-3DB4-E040-BB89AD431E0C","latestVersionIndicator":"Yes","beginDate":"2010-12-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-12-27","modifiedBy":"ONEDATA","dateModified":"2010-12-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"986ADE98-70C3-3DB4-E040-BB89AD431E0C","latestVersionIndicator":"Yes","beginDate":"2010-12-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-12-27","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4104903","version":"1","longName":"GOG-0170R","context":"NRG"},{"publicId":"10000427","version":"1","longName":"GOG-0170R","context":"NRG"},{"publicId":"10000426","version":"1","longName":"GOG-0170R","context":"NRG"},{"publicId":"4104881","version":"1","longName":"GOG-0227G","context":"NRG"},{"publicId":"4104890","version":"1","longName":"GOG-0229L","context":"NRG"},{"publicId":"4104893","version":"1","longName":"GOG-0230D","context":"NRG"},{"publicId":"4104889","version":"1","longName":"GOG-0229K","context":"NRG"},{"publicId":"10000078","version":"1","longName":"GOG-0186H","context":"NRG"},{"publicId":"10000077","version":"1","longName":"GOG-0186H","context":"NRG"},{"publicId":"4104904","version":"1","longName":"GOG-0186H","context":"NRG"},{"publicId":"10000081","version":"1","longName":"GOG-0186J","context":"NRG"},{"publicId":"4104906","version":"1","longName":"GOG-0186J","context":"NRG"},{"publicId":"10000082","version":"1","longName":"GOG-0186J","context":"NRG"},{"publicId":"10000430","version":"1","longName":"GOG-0186I","context":"NRG"},{"publicId":"10000429","version":"1","longName":"GOG-0186I","context":"NRG"},{"publicId":"4104905","version":"1","longName":"GOG-0186I","context":"NRG"},{"publicId":"10000346","version":"1","longName":"GOG-0186K","context":"NRG"},{"publicId":"10000345","version":"1","longName":"GOG-0186K","context":"NRG"},{"publicId":"4104907","version":"1","longName":"GOG-0186K","context":"NRG"},{"publicId":"4104891","version":"1","longName":"GOG-0229N","context":"NRG"},{"publicId":"10000281","version":"1","longName":"GOG-0280","context":"NRG"},{"publicId":"10000282","version":"1","longName":"GOG-0280","context":"NRG"},{"publicId":"4104929","version":"1","longName":"GOG-0280","context":"NRG"},{"publicId":"4104886","version":"1","longName":"GOG-0265","context":"NRG"},{"publicId":"4104892","version":"1","longName":"GOG-0229O","context":"NRG"},{"publicId":"4104938","version":"1","longName":"GOG-0254","context":"NRG"}]}],"AlternateNames":[{"name":"GOG","type":"USED_BY","context":"NRG"},{"name":"3178966v1.0:2404918v1.0","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"CRF Text2","type":"Alternate Question Text","description":"Has the patient received any non-cytotoxic chemotherapy for management of recurrent or persistent disease, with the exception of hormonal therapy?","url":null,"context":"CTEP"},{"name":"Has the patient received any","type":"Preferred Question Text","description":"Has the patient received any non-cytotoxic chemotherapy for management of recurrent or persistent disease","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Has the patient received any non-cytotoxic chemotherapy (biologic/targeted agents) for management of recurrent or persistent disease?","url":null,"context":"CTEP"},{"name":"CRF Text6","type":"Alternate Question Text","description":"Has the patient received any biologic/targeted therapy?","url":null,"context":"CTEP"},{"name":"CRF Text5","type":"Alternate Question Text","description":"Has the patient received any biologic/targeted (non-cytotoxic) therapy targeting the VEGF and/or PDGF pathways for management of recurrent or persistent disease?","url":null,"context":"CTEP"},{"name":"CRF Text4","type":"Alternate Question Text","description":"Has the patient received any biologic/targeted (non-cytotoxic) therapy as part of their primary therapy and/or as part of their therapy for advanced, metastatic, or recurrent disease?","url":null,"context":"CTEP"},{"name":"CRF Text3","type":"Alternate Question Text","description":"Has the patient received any non-cytotoxic (biologic or targeted) agents as part of their primary treatment or for management of recurrent or persistent disease?","url":null,"context":"CTEP"},{"name":"CRF Text7","type":"Alternate Question Text","description":"Has the patient received any biologic/targeted (non-cytotoxic) therapy for management of recurrent or persistent disease?","url":null,"context":"CTEP"},{"name":"CRF Text9","type":"Alternate Question Text","description":"Has the patient received any biologic/targeted (non-cytotoxic) therapy targeting the VEGF pathway for management of recurrent or persistent disease?","url":null,"context":"CTEP"},{"name":"CRF Text8","type":"Alternate Question Text","description":"Has the patient received any biologic/targeted (non-cytotoxic) therapy targeting the VEGF and/or MET pathways for management of recurrent or persistent disease?","url":null,"context":"CTEP"},{"name":"CRF Text10","type":"Alternate Question Text","description":"Has the patient received any non-cytotoxic (biologic or targeted) agent(s) as part of initial treatment and/or for management of recurrent or persistent disease?","url":null,"context":"NRG"},{"name":"NRG_CRF Text","type":"Alternate Question Text","description":"Has the patient received any non-cytotoxic therapy for management of recurrent or persistent disease?","url":null,"context":"NRG"},{"name":"CRF Text 11","type":"Alternate Question Text","description":"Has the patient completed prior non-cytotoxic chemotherapy (e.g. small molecule inhibitor) at least 28 days prior to registration?","url":null,"context":"CTEP"},{"name":"NRG_eCRF_Text","type":"Alternate Question Text","description":"Has the patient completed prior non-cytotoxic chemotherapy (e.g. small molecule inhibitor) at least 28 days prior to Step 2 registration?","url":null,"context":"NRG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"987BC23A-9A5B-BDCF-E040-BB89AD434266","latestVersionIndicator":"Yes","beginDate":"2010-12-28","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-12-28","modifiedBy":"BOWSERC","dateModified":"2021-12-09","changeDescription":"Replaced VD Diagnosis Ind-2 2404918v1 with VD ID#3506068 - Yes No Indicator  - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}